World's Best Scientists 2026 revealed!
Pierfranco Conte

Pierfranco Conte

D-Index & Metrics

Medicine

D-Index
103
Citations
48520
World Ranking
7241
National Ranking
241

Pierfranco Conte publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Pierfranco Conte sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 942 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Pierfranco Conte D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Pierfranco Conte sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Pierfranco Conte is affiliated with the University of Padua in Italy. Their research primarily focuses on medicine and biochemistry, genetics, and molecular biology, with a significant emphasis on oncology, pulmonary and respiratory medicine, cancer research, genetics, and radiology, nuclear medicine, and imaging.

The main topics addressed in Conte's work include:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Cancer Treatment and Pharmacology

Conte has coauthored extensively with colleagues such as Valentina Guarneri, Maria Vittoria Dieci, Gaia Griguolo, Giulia Pasello, and Federica Miglietta. Their collaborations have contributed to a diverse and prolific research output.

Frequently publishing in venues relevant to oncology and cancer research, Conte's work appears in:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • ESMO Open
  • Cancers

Notable recent papers by Conte include:

  • "Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations," 2020, New England Journal of Medicine
  • "Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1," 2020, Annals of Oncology
  • "Evolution of HER2-low expression from primary to recurrent breast cancer," 2021, npj Breast Cancer
  • "A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer," 2020, Clinical Cancer Research
  • "Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment," 2022, ESMO Open

Best Publications

  • Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

    H. von der Maase;S.W. Hansen;J.T. Roberts;L. Dogliotti

  • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu

  • Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

    Michael Marty;Francesco Cognetti;Dominique Maraninchi;Raymond Snyder

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

    José Baselga;Karen A. Gelmon;Shailendra Verma;Andrew Wardley

  • The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial

    George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn

  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    M.E. Robson;N. Tung;P. Conte;S.-A. Im

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Paul K. Paik;Enriqueta Felip;Remi Veillon;Hiroshi Sakai

  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

    Sung-Bae Kim;Rebecca Dent;Seock-Ah Im;Marc Espié

  • Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

    M. V. Dieci;M. V. Dieci;C. Criscitiello;A. Goubar;G. Viale

  • Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

    J M Nabholtz;K Gelmon;M Bontenbal;M Spielmann

  • Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

    Valentina Guarneri;Antonio Frassoldati;Alberto Bottini;Katia Cagossi

  • Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    Edith A. Perez;Carlos Barrios;Wolfgang Eiermann;Masakazu Toi

  • Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    F. André;E.M. Ciruelos;D. Juric;S. Loibl

  • Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

    Eva Thomas;Josep Tabernero;Monica Fornier;Pierfranco Conté

  • Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.

    PierFranco Conte;Valentina Guarneri

  • Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

    M. V. Dieci;M. C. Mathieu;V. Guarneri;P. Conte

  • Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Javier Cortés;Pierre Fumoleau;Giulia Valeria Bianchi;Teresa M. Petrella

Frequent Co-Authors

Massimo Dominici
Massimo Dominici University of Modena and Reggio Emilia
Alfredo Falcone
Alfredo Falcone University of Pisa
Mario Campone
Mario Campone Grenoble Alpes University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Stefano Indraccolo
Stefano Indraccolo Istituto Oncologico Veneto
Paolo Bruzzi
Paolo Bruzzi Ospedale San Martino
Andrea Ardizzoni
Andrea Ardizzoni University of Bologna
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Romano Danesi
Romano Danesi University of Pisa
Dino Amadori
Dino Amadori University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA opens doors to a variety of related online degrees and alternative healthcare pathways. For those interested in nutrition, an online dietitian degree can help lay the foundation for roles in clinical nutrition, wellness programs, or food science from a flexible, remote format.

For aspiring administrators, choosing which online healthcare degree programs are recognized for their accreditation by cahme? is crucial, as employers in hospital management and health policy value recognized, credible credentials.

Registered nurses looking to upskill have the option of pursuing an rn to bsn without clinicals path, allowing career advancement with maximum scheduling flexibility.

Meanwhile, advanced practitioners may consider the shortest dnp programs to achieve a Doctorate of Nursing Practice in less time.

Each pathway offers unique advantages, whether your aim is direct patient care, management, or specialized wellness roles. Be sure to research accreditation and program length to find your ideal fit in this rapidly evolving field.

Best Scientists Citing Pierfranco Conte

Trending Scientists

Recently Published Articles